Pre-market · Oct 8, 8:20 am ET · After hours $9.82 0.00%
Open$9.77
Prev close$9.83
Day range$9.60 – $10.14
Volume1.32M
Market cap$610.35M
P/E (TTM)–
Dividend yield–
SLN Stock News
Headlines matching Silence Therapeutics or the SLN ticker, most recent first.
H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75Market news · 22 Sep 2026 · Direct mention
William Blair Maintains Silence Therapeutics(SLN.US) With Buy RatingMarket news · 11 Sep 2026 · Direct mention
Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy RatingMarket news · 17 Aug 2026 · Direct mention
Silence Therapeutics Expects Offering to Close on or About Aug. 13 SLNDow Jones · 12 Aug 2026 · Direct mention
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $32Market news · 11 Aug 2026 · Direct mention
A Quick Look at Today's Ratings for Silence Therapeutics(SLN.US), With a Forecast Between $27 to $75Market news · 11 Aug 2026 · Direct mention
Cantor Fitzgerald Initiates Silence Therapeutics(SLN.US) With Buy RatingMarket news · 24 Jun 2026 · Direct mention
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $25Market news · 12 Jun 2026 · Direct mention
Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $27NegativeMarket news · 8 May 2026 · Direct mention
Silence Therapeutics (SLN) Receives a Buy From H.C. WainwrightTipRanks · 27 May 2026 · Direct mention
H.C. Wainwright Reaffirms Their Buy Rating on Silence Therapeutics (SLN)TipRanks · 7 Apr 2026 · Direct mention
William Blair Maintains Silence Therapeutics(SLN.US) With Buy Rating, Announces Target Price $5.5Market news · 6 Mar 2026 · Direct mention
Goldman Sachs Maintains Silence Therapeutics(SLN.US) With Sell Rating, Maintains Target Price $4Market news · 6 Mar 2026 · Direct mention
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Medline, Inc. Class A (MDLN) and Silence Therapeutics (SLN)TipRanks · 26 Feb 2026 · Direct mention
BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $15NegativeMarket news · 14 Jun 2025 · Direct mention
Discussion
No comments yet — be the first to weigh in on SLN.
No comments yet — be the first to weigh in on SLN.